Safety and efficacy of a pre-treatment antiplatelet regimen of unruptured intracranial aneurysms: a single-center experience
- 13 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Neuroradiology
- Vol. 62 (8), 1029-1041
- https://doi.org/10.1007/s00234-020-02387-y
Abstract
Purpose Endovascular treatment of unruptured intracranial aneurysms with stent-assisted coiling or flow diverter stents requires a prophylactic antiplatelet premedication to avoid thrombo-embolic complications. Guidelines for optimal antiplatelet regimens are poorly defined. The aim of this study is to report our experience using a high dosage antiplatelet premedication regimen for patients with unruptured intracranial aneurysms undergoing endovascular treatment by stent-assisted coiling or flow diverter stents. Methods From a retrospective analysis of a prospectively maintained database, we collected clinical and angiographic data of 400 procedures in 362 patients treated by stent-assisted coiling or flow diverter stents for 419 unruptured intracranial aneurysms. Descriptive and analytic statistics were performed to report morbidity, mortality, and complication rates and to demonstrate associations between variables and outcomes. Logistic multivariable regression was performed to rule out confounding factors between subgroups. Results Thrombo-embolic complications occurred in 23/400 procedures (5.75%) and hemorrhagic complications in 19/400 procedures (4.75%). The majority of complications were minor and transient with overall procedure-related morbidity and mortality rates of 1.75% (n = 7/400) and 1.25% (n = 5/400) respectively. The co-existence of multiple cardiovascular risk factors among smoking, hypertension, dyslipidemia, and age > 65 years old was significantly associated with permanent procedure-related morbidity (p = 0.006) and thrombo-embolic complications occurrence (p = 0.034). Age alone was associated with higher permanent morbidity (p = 0.029) and was the only variable associated with higher hemorrhagic complication (p = 0.024). Conclusion In this study, the use of a high dosage antiplatelet premedication was safe and effective for the treatment of unruptured intracranial aneurysms with stent-assisted coiling or flow diverter stents. Mortality and morbidity rates compare favorably with the current literature. The thrombo-embolic complications rate is low and most of them were clinically silent. However, the hemorrhagic complications rate was substantial and a significant proportion of them were associated with mortality.This publication has 27 references indexed in Scilit:
- Management of antiplatelet therapy in patients undergoing neuroendovascular proceduresJournal of Neurosurgery, 2018
- Relationship between adverse events and antiplatelet drug resistance in neurovascular intervention: a meta-analysisJournal of NeuroInterventional Surgery, 2018
- Insufficient platelet inhibition and thromboembolic complications in patients with intracranial aneurysms after stent placementJournal of Neurosurgery, 2016
- Flow-diverter devices in the treatment of intracranial aneurysms: A meta-analysis and systematic reviewThe Neuroradiology Journal, 2016
- Guidelines for the Management of Patients With Unruptured Intracranial AneurysmsStroke, 2015
- Heterogeneous practice patterns regarding antiplatelet medications for neuroendovascular stenting in the USA: a multicenter surveyJournal of NeuroInterventional Surgery, 2014
- Clopidogrel Resistance Is Associated with Thromboembolic Complications in Patients Undergoing Neurovascular StentingAmerican Journal of Neuroradiology, 2012
- Stent-Supported Aneurysm Coiling: A Literature Survey of Treatment and Follow-UpAmerican Journal of Neuroradiology, 2011
- Standardized Bleeding Definitions for Cardiovascular Clinical TrialsCirculation, 2011
- International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusionThe Lancet, 2005